Previous close | 9.45 |
Open | 10.88 |
Bid | 10.40 |
Ask | 10.90 |
Strike | 44.00 |
Expiry date | 2025-03-21 |
Day's range | 10.88 - 10.88 |
Contract range | N/A |
Volume | |
Open interest | 252 |
A Relative Strength Rating upgrade for Bristol Myers Squibb shows improving technical performance. Will it continue?
Shattuck stock plunges as it discontinues the clinical development of SL-172154 for two blood cancer indications and plans to reduce the workforce by 40%.
Prime Medicine collaborates with Bristol Myers Squibb for the development of T-cell therapies. Shares gain.